ALG-1001 (Luminate®, Allegro Ophthalmics), a first-in-class integrin peptide therapy, met the primary endpoint of vision non-inferiority to bevacizumab (Avastin, Genentech Inc.), an anti-vascular endothelial growth factor therapy (anti-VEGF), with 12-week durability in a population of patients with mostly chronic diabetic macular edema (DME).
ALG-1001 seems to be a strong player with different mechanisms of action that benefit patients who have been receiving chronic anti-VEGF therapy and those who are treatment naïve.
To read the article, please visit Ophthalmology Times: “ALG-1001: Turning off the machinery of angiogenesis”
